2. Summary
Biosimilar development has failed to meet expectations in recent years, but that
is set to change.
With a new U.S. biosimilars approval pathway imminent, and the expiration of
many top-selling biologics on the horizon, existing biosimilar developers and
newcomers are highly motivated to invest in the biosimilar field and are turning
their attention to more complex biologics, such as monoclonal antibodies. Global
sales of biologics are projected to reach $200bn in 2014 (from $138bn in
2010), making it a potentially lucrative market for biosimilar developers.
Originator, generics, and biosimilar companies alike need to be informed about
the latest development trends and to know the likely patent expiration of
marketed products and status of products in development. However, market
intelligence has been widely dispersed, making it very difficult for companies to
assess potential competition and areas of opportunity, until now.
FirstWord has gathered the very latest intelligence from BIOPHARMA, the
Orange Book, literature, industry associations, company websites, and many
other secondary sources to provide a single, authoritative guide to currently
marketed and in-development biosimilar products.
Report Overview
In Charting the Biosimilar and Biobetter Development Pipeline , you’ll find details
of currently marketed biosimilar and biobetter drugs, and all biosimilar and
biobetter drugs known to be in clinical development.
Through more than 60 intuitive tables and charts, you will receive unique insights
into high-level trends and significant
http://www.aarkstore.com/
3. Summary
Key Report Features
More than 60 exclusive tables and charts, offering a complete and illuminating
view of the biosimilar pipeline
Up-to-the-minute details of ALL biosimilars/biobetters known to be in
development in US and EU markets, with their development status and earliest
potential launch dates
Information on international biogenerics that may seek approval as
biosimilars/biobetters in US and EU markets
Comprehensive list of reference products, with key sales data and expected
patent expiration dates
Detailed analysis of the biosimilar pipeline and market by reference
products, therapeutic area, drug class, and compound class
Reports showing the most active companies, regions, and countries
Insights into areas of most intense competition and greatest potential opportunity
Concise commentary highlighting key findings, and providing valuable market
intelligence
Definitions of key terms and concepts
http://www.aarkstore.com/
4. Table of Contents:
Executive summary
Introduction
Definitions and methodology
Scope and coverage
Glossary
Methodology
Patents
Indexing by indication
Indexing by phase of development
Nomenclature
Reference products
Top20 Reference Products
Biosimilars in development
Biosimilars by earliest potential launch date — US & EU
Biosimilars by class and earliest potential launch date in the US (total number)
Biosimilars by class and earliest potential launch date in the EU (total number)
Biosimilar developers countries and regions
Biosimilars in development by drug class
http://www.aarkstore.com/
5. Table of Contents:
Biobetters in development
Biobetter developments by compound class and therapy area
Biobetter development by therapy area and stage
Biobetters by class and earliest potential launch in the US
Biobetters by class and earliest potential launch in the EU
Biobetter developers by compound class
Biobetter development pipeline by compound class
Immunomodulators
Interferons
mAb Immunomodulators
Cytotoxic mAbs
Erythropoietins
Others (Enzymes, Blood Clotting Factors)
Other Hormones (excluding insulins)
Biobetter development pipeline by therapy area
Autoimmune disease
Autoinflammatory disease
Cardiovascular diseases
http://www.aarkstore.com/
6. More Related Reports :
Charting the Biosimilar and Biobetter Development Pipeline
Active Pharmaceutical Ingredients (API) Market in the Americas to 2017
- Shift Towards Generics and Biosimilars as South and Central America
Emerges as a Key Growth Region
Biosimilars in Developed Countries - Launch of Biosimilar mAbs in
Europe and New Regulatory Pathways in the US to Spur Market Growth
Global Biosimilars Market Report: 2012 Edition
Biosimilars in Emerging Economies - Advanced Recombinant
Technology Platforms and Low Cost Manufacturing Put India and China
at a Strategic Advantage in Biosimilar Production
Biosimilars: Current Situation & Future Prospects, Worldwide
Global Biosimilar Market 2010-2014
http://www.aarkstore.com/
7. For More details about above & other Reports plz contact :
http://www.aarkstore.com/reports/Charting-the-Biosimilar-
and-Biobetter-Development-Pipeline-99086.html
Contact : Pranali
Aarkstore.com
Mob.No.918149852585
Email: enquiry@aarkstore.com
You can also request for sample page of above mention
reports on sample@aarkstore.com
http://www.aarkstore.com/
